Syncom Formulations (India) Limited (NSE:SYNCOMF)

Market Cap	12.80B -22.8%
Revenue (ttm)	5.03B +28.6%
Net Income	689.58M +76.2%
EPS	0.70 +75.0%
Shares Out	n/a
PE Ratio	18.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	684,551
Average Volume	1,800,841
Open	13.60
Previous Close	13.59
Day's Range	13.21 - 13.60
52-Week Range	11.65 - 23.49
Beta	0.57
RSI	49.68
Earnings Date	Feb 12, 2026

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 744
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYNCOMF

Financial Performance

In fiscal year 2025, NSE:SYNCOMF's revenue was 4.65 billion, an increase of 76.55% compared to the previous year's 2.63 billion. Earnings were 494.35 million, an increase of 95.28%.